SAR245408 + MSC1936369B

**SAR245408 + MSC1936369B** is a combination of two investigational oral small molecule drugs developed for the treatment of advanced or metastatic solid tumors. **SAR245408** (also known as XL147) is a selective, reversible, pan-class I phosphoinositide 3-kinase (PI3K) inhibitor that targets the PI3K/AKT signaling pathway, which is frequently deregulated in cancer[5]. **MSC1936369B** (also known as AS703026) is a selective mitogen-activated protein kinase kinase (MEK) inhibitor targeting the MAPK/ERK pathway, another critical signaling pathway implicated in cancer growth and survival[3][8]. The rationale for their combined use is to target two major oncogenic pathways (PI3K/AKT and MAPK/ERK) that are often co-activated or mutated in solid tumors, with the goal of overcoming resistance mechanisms and enhancing antitumor activity[4][1][8]. The combination was evaluated in phase 1 studies by Sanofi and Merck KGaA, aiming to determine the maximum tolerated dose, safety, and preliminary antitumor activity in patients with a range of solid tumors[4][1][6]. The program was terminated early due to deprioritization, and the drugs have not advanced beyond early-stage clinical trials[4].

Other names

SAR245408 + MSC1936369BXL147 + MSC1936369BPI3K inhibitor + MEK inhibitor combination